SBIR/STTR Research Award
Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery
Award amount
$600,000Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2022Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- MONTANA MOLECULAR LLC
- Proposal award date
- 2022-05-13
- Contract end date
- 2024-04-30
- UEI
- KN3BF8Y27ES3
- Solicitation number
- PA21-259
- Topic code
- NIAID
Research abstract
SUMMARY STATEMENT
The SARS-CoV-2 virus depends upon two proteases for replication, 3CLpro and
PLpro. If one or both of these proteases can be blocked, COVID-19 infection can be
effectively treated. Montana Molecular makes and sells live cell, fluorescent
biosensor assays for disease research and drug discovery. In response to the
COVID-19 pandemic, Montana Molecular applied its expertise and background in
live cell assay development to build fluorescent biosensors for the SARS-CoV-2
main protease, 3CLpro. The prototype sensor described in this proposal
demonstrates feasibility. Direct to Phase II support is requested here to speed the
development of even brighter, more sensitive assays for the 3CLpro and PLpro
proteases. These assays can be used in high throughput screening for compounds
that inhibit the protease, and engage with their target in living, human cells.
406-539-7399 366 Gallatin Park Drive Suite A Bozeman, MT 59715
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Fluorescent Biosensors for measuring the signaling kinetics of GPCR ligands that activate G12/13 pathways.
- An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder
- An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder
- A robust assay for detecting agonist bias in living cells.
- I-Corps Proposal for Commercialization of Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
14 SBIR/STTR records share this UEI (2007–2025). Reported award amounts total $6,693,315. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, National Science Foundation